Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Google Secures Pentagon AI Deal for Classified Projects 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that the Company will be presenting at the 18th Annual BIO CEO & Investor Conference taking place February 8 - 9, 2016 at the Waldorf Astoria in New York, NY. Ocera’s management will present at 10:00 AM ET on Tuesday, February 9th, in the Conrad room in the conference’s Orphan/Rare Diseases track.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
Susan Sharpe Ocera Therapeutics, Inc. [email protected] 919-328-1109
